All company sites gemabank.ru celltranspl.ru reprobank.ru genetico.ru stem-cells.ru sprs-therapy.ru celltech.ru neovasculgen.ru Russian English About company Press Center Directions Products Investors 20.09 Vascular surgeons voted for gene therapy On September 14, 2018, at the international conference "Prospects for the development of vascular surgery in the country and its regions", the results of a large-scale interactive voting showed that vascular surgeons consider gene therapy to be a promising and popular method of treating ischemia. 29.08 HSCI Consolidated Results for 1H 2018 under IFRS HSCI PJSC announces its consolidated results of operations for the 1st half of 2018 (6 months ended June 30, 2018) in accordance with International Financial Reporting Standards (IFRS). All news HUMAN STEM CELL INSTITUTE (PJSC "HSCI") The Human Stem Cell Institute (PJSC "HSCI") is a Russian public company founded in 2003 and working in the field of modern biomedical technologies and healthcare. Today the Company has a holding structure: the parent company is PJSC HSCI, the issuer of the RII sector of the Moscow Exchange (ticker: ISKJ ), and 8 subsidiaries, 3 of which are residents of Skolkovo. HSCI's areas of activity are research, development, as well as commercialization and further promotion on the market of its own innovative medicines and high-tech services in the field of regenerative medicine, medical genetics (including reproductive), gene therapy, bioinsurance and biopharmaceuticals. The company aims to create a new culture of medical care for a person - the development of healthcare in the field of personalized and preventive medicine. HSCI owns the bank for personal storage of cord blood stem cells Gemabank ® - the largest in the Russian Federation and the CIS, as well as the bank of human reproductive cells - Reprobank ® (personal storage and donation). Компания вывела на рынок Неоваскулген® – первый в мире препарат, механизм действия которого представляет новую методику лечения ишемических заболеваний - «терапевтический ангиогенез» (лечебный рост сосудов), а также SPRS-терапию® – инновационную медицинскую технологию применения дермальных аутофибробластов для восстановления кожи с признаками возрастных и иных структурных изменений. ИСКЧ реализует социально-значимый проект Genetico® по развитию персонализированной медицины в области диагностики и профилактики наследственных заболеваний и генетически обусловленных репродуктивных патологий. Линейка услуг генетических исследований и консультирования с целью раннего выявления и профилактики наследственных заболеваний, а также патологий с генетической составляющей, в т.ч. в репродуктивной сфере, включает, преимплантационный генетический скрининг / преимплатационную генетическую диагностику, неинвазивное пренатальное исследование, диагностические панели и тесты на отдельные категории и случаи заболеваний, геномный анализ на базе NGS для исследовательских и медицинских целей и др. The range of Genetico ® services is provided on the basis of a new laboratory and production complex created by HSCI in Moscow in 2013. The company aims to develop its products in the Russian and world markets. HSCI's initial public offering in December 2009 was the first IPO of a biotech company in Russia. Disclaimer List of insider information © 2003-2018 Human Stem Cell Institute Information disclosure of PJSC "HSCI" on the website of LLC "Interfax-TsRKI"